Is Inovio (Ino) stock set to rebound?
Inovio spinoff Geneos Therapeutics raises $17M to expand cancer treatment study Geneos Therapeutics, a clinical stage biotherapeutics company spun out of Inovio Pharmaceuticals, raised $17 million...
What has Inovio been working on?
Apr 19, 2022 · Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Inovio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add. $3.09. +0.12 (+4.04%) (As of 04/19/2022 12:26 PM ET) Today's Range. $2.95.
Will Inovio’s VGX-3100 be another winning year for stocks?
Apr 11, 2022 · INO | Complete Inovio Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
How can I get the latest news and ratings for Ino?
Shares of the clinical-stage biotech Inovio Pharmaceuticals ( INO-3.06%) are up by a healthy 20.3%, on abnormally high volume, as of 10:40 a.m. …
Why is inovio stock going up?
[Updated: Oct 13, 2021] INO Stock Rise This can be attributed to delays in trials for INO-4800, the company's Covid-19 vaccine candidate.Dec 17, 2021
How high is inovio stock expected to go?
Based on 6 Wall Street analysts offering 12 month price targets for Inovio Pharmaceuticals in the last 3 months. The average price target is $11.80 with a high forecast of $30.00 and a low forecast of $3.00. The average price target represents a 288.16% change from the last price of $3.04.
Is INO stock a good buy?
Is Inovio stock a buy today? Inovio's stock could become a great buy if INO-4800 is successful and the Food and Drug Administration (FDA) approves the vaccine.Jan 20, 2021
Is inovio a shorted stock?
24.05% of Inovio Pharmaceuticals' shares are currently sold short.
What is the future of INO?
The 7 analysts offering 12-month price forecasts for Inovio Pharmaceuticals Inc have a median target of 6.00, with a high estimate of 30.00 and a low estimate of 3.00. The median estimate represents a +86.34% increase from the last price of 3.22.
Does Inovio stock go up tomorrow?
NEWS for Inovio Pharmaceuticals, Inc. Click here for more Support & Resistance levels for Inovio Pharmaceuticals, Inc....Munafa value: 40 as on 08 Fri Apr 2022.Strong resistance18Strong resistance17Strong resistance16Strong resistance14Strong resistance1311 more rows
Is inovio a buy Zacks?
See rankings and related performance below. The VGM Score are a complementary set of indicators to use alongside the Zacks Rank....Momentum Scorecard. More Info.Zacks RankDefinitionAnnualized Return1Strong Buy24.93%2Buy18.44%3Hold9.99%4Sell5.61%2 more rows
Will inovio get FDA approval?
INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.Nov 9, 2021
Who owns Inovio Pharmaceuticals?
Top 10 Owners of Inovio Pharmaceuticals IncStockholderStakeShares ownedSSgA Funds Management, Inc.10.49%23,267,928BlackRock Fund Advisors7.05%15,637,463The Vanguard Group, Inc.4.83%10,703,079D. E. Shaw & Co. LP2.70%5,985,5336 more rows
Is Ino short squeeze?
In February, INO stock soared after a Reddit user called for a short squeeze of the stock. Also helping the biotech company: BlackRock, an investment management firm, upped its stake to more than 14.2 million shares. It now owns 8.4% of Inovio.Dec 21, 2021
Is nikola shorted?
Nikola is third most shorted stock among truck makers, electric-car makers.Nov 30, 2020
Is nikola a short squeeze?
You know, Nikola is one of them that we see a lot of chatter about and we see a higher short interest and some recent losses in the name, so it is a more squeezable stock.Dec 27, 2021
Inovio's shares are on the mend today
What happened
George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.
So what
Shares of the clinical-stage biotech Inovio Pharmaceuticals ( NASDAQ:INO) are up by a healthy 20.3%, on abnormally high volume, as of 10:40 a.m. EDT Tuesday. Today's double-digit rally appears to be carryover from CEO Dr. Joseph Kim's presentation yesterday at the H.C. Wainwright 22nd Annual Global Investment Conference.
Now what
Inovio's shares have been under immense pressure for the past three months. In fact, the drugmaker's stock has fallen by nearly 60% relative to its 52-week high posted back in June.
What is Prosper's passion?
Should investors buy into this latest rally? Inovio is a risky biotech stock to be sure. But there's a decent chance that the biotech could indeed land a sizable award for its COVID-19 vaccine. So, if you're the risk-tolerant type, it might be worthwhile to buy a few shares ahead of this potential catalyst.
When did Inovio release its second quarter financials?
Passionate about teaching and learning, he enjoys helping others make better decisions about their finances -- and enjoys it just as much when they return the favor. In his free time, you'll find him curling up with a good book or doing math.
Is Inovio stock volatile?
Inovio released its second-quarter financial report on Aug. 10. The big story from the company's earnings release was an update regarding its efforts to develop a vaccine for COVID-19. Inovio reported that in a phase 1 clinical trial, all of the participants demonstrated immune responses after receiving its experimental vaccine, INO-4800. In particular, about 90% of the study's participants generated strong T cell responses. Also, Inovio's candidate performed well in a non-human primate study as part of Operation Warp Speed.
What is Prosper's passion?
Inovio's stock will continue to be volatile moving forward. The progress of its COVID-19 program will spell good news for its shareholders, but several things could send its stock tumbling, including the work of other biotechs in the COVID-19 battle. For that reason, Inovio remains a high-risk, high-reward play. Those who can stomach the risk and decide to initiate a position in the company could rack up solid gains between now and the end of the year.
Is Inovio testing the INO-4800?
Passionate about teaching and learning, he enjoys helping others make better decisions about their finances -- and enjoys it just as much when they return the favor. In his free time, you'll find him curling up with a good book or doing math.
Is Inovio a drug company?
Inovio recently kicked off a phase 1 clinical trial to test the safety of its investigational COVID-19 vaccine, INO-4800. The trial -- which will involve up to 40 healthy adult volunteers -- will also test the vaccine's ability to trigger an immune response in the body. During the CNBC interview with Jim Cramer, Kim said the company plans to finish enrolling volunteers for the trial before the end of the month.
Is there another 1,000 point drop in the Dow?
Inovio is a prospector. It’s not a drug company. It designs molecules, based on good science, that can then go into the testing pipeline. Any investment in INO stock is a bet on that and nothing more.
